Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

328 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Lung cancer.
Herbst RS, Heymach JV, Lippman SM. Herbst RS, et al. N Engl J Med. 2008 Sep 25;359(13):1367-80. doi: 10.1056/NEJMra0802714. N Engl J Med. 2008. PMID: 18815398 Review. No abstract available.
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Komaki R, et al. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):46-9. doi: 10.1053/srao.2002.31363. Semin Radiat Oncol. 2002. PMID: 11917284 Clinical Trial.
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial.
Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zacarola P, Dang NH, Leong T, Salgia R, Skarin AT. Herbst RS, et al. Cancer Chemother Pharmacol. 2001 Aug;48(2):151-9. doi: 10.1007/s002800100282. Cancer Chemother Pharmacol. 2001. PMID: 11561781 Clinical Trial.
Chemotherapy for advanced non-small cell lung cancer.
Herbst RS, Dang NH, Skarin AT. Herbst RS, et al. Hematol Oncol Clin North Am. 1997 Jun;11(3):473-517. doi: 10.1016/s0889-8588(05)70445-7. Hematol Oncol Clin North Am. 1997. PMID: 9209907 Review.
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro CarpeƱo J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Kozloff MF, et al. Br J Cancer. 2012 Oct 9;107(8):1277-85. doi: 10.1038/bjc.2012.406. Epub 2012 Sep 18. Br J Cancer. 2012. PMID: 22990652 Free PMC article. Clinical Trial.
Lung cancer in patients under age 40.
Skarin AT, Herbst RS, Leong TL, Bailey A, Sugarbaker D. Skarin AT, et al. Lung Cancer. 2001 Jun;32(3):255-64. doi: 10.1016/s0169-5002(00)00233-6. Lung Cancer. 2001. PMID: 11390007
Emerging therapies in non-small-cell lung cancer.
Khuri FR, Herbst RS, Fossella FV. Khuri FR, et al. Ann Oncol. 2001 Jun;12(6):739-44. doi: 10.1023/a:1011197500223. Ann Oncol. 2001. PMID: 11484947 Review.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.
Gettinger SN, Choi J, Mani N, Sanmamed MF, Datar I, Sowell R, Du VY, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm DL, Chen L, Herbst RS, Schalper KA. Gettinger SN, et al. Nat Commun. 2018 Aug 10;9(1):3196. doi: 10.1038/s41467-018-05032-8. Nat Commun. 2018. PMID: 30097571 Free PMC article.
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ. Heymach JV, et al. Ann Oncol. 2014 Oct;25(10):1941-8. doi: 10.1093/annonc/mdu269. Epub 2014 Jul 23. Ann Oncol. 2014. PMID: 25057173 Free PMC article. Clinical Trial.
328 results
Jump to page
Feedback